We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+2.13%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$125M
Cap. Flow %
103.89%
Top 10 Hldgs %
69.16%
Holding
19
New
19
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$11.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$11M
3
TSVT
2seventy bio
TSVT
+$9.66M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$9.37M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$8.51M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
1
Crinetics Pharmaceuticals
CRNX
$8.88B
$11.3M 9.41%
+623,819
New +$11M
TSVT
2
DELISTED
2seventy bio
TSVT
$9.89M 8.2%
+684,996
New +$9.66M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$9.41M 7.81%
+212,329
New +$11.3M
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.44B
$8.79M 7.29%
+487,179
New +$8.51M
CYTK icon
5
Cytokinetics
CYTK
$10.7B
$7.97M 6.62%
+196,982
New +$8.48M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.5B
$7.95M 6.6%
+68,404
New +$7.94M
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.37M 6.12%
+269,827
New +$7.37M
ITOS
8
DELISTED
iTeos Therapeutics
ITOS
$7.03M 5.83%
+342,071
New +$6.68M
ALBO
9
DELISTED
Albireo Pharma Inc
ALBO
$6.86M 5.7%
+341,827
New +$7.22M
KDNY
10
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$6.73M 5.58%
+423,177
New +$9.37M
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$6.7M 5.56%
+719,937
New +$3.86M
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$5.72M 4.75%
+1,611,778
New +$6.13M
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.68M 4.71%
+69,170
New +$5.75M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$5.37M 4.45%
+156,085
New +$5.96M
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$4.89M 4.06%
+566,179
New +$6.37M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.32B
$3.75M 3.11%
+340,163
New +$4.24M
BIIB icon
17
Biogen
BIIB
$29.5B
$2.17M 1.8%
+7,660
New +$2.16M
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$1.56M 1.29%
+169,493
New +$1.75M
TBPH icon
19
Theravance Biopharma
TBPH
$871M
$1.33M 1.11%
+141,339
New +$1.49M

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
FWM
FFT Wealth Management Philadelphia, Pennsylvania $552M AUM 16.82% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return

Saturn V Capital Management's Q4 2022 Portfolio in Review

Q4 2022 is the first quarter with a 13F filing on record for Saturn V Capital Management, which disclosed 19 positions worth $121M. Its ten largest holdings account for 69% of the portfolio.

Its largest position is Apellis Pharmaceuticals: 212,329 shares worth $9.41M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Saturn V Capital Management's largest Q4 2022 buy was Apellis Pharmaceuticals: 212,329 shares worth $9.41M.
  • Saturn V Capital Management's ten largest holdings make up 69% of its $121M portfolio in Q4 2022.
  • Saturn V Capital Management disclosed 19 positions in Q4 2022, its first 13F filing on record.

Based on Saturn V Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.